BioCentury | Jan 23, 2021
Politics, Policy & Law

CMS rule should improve biosimilar Part D access, but isn’t silver bullet

...to biosimilars competing with the originator products. The prime example is the ongoing litigation between Pfizer...
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...CDC said the second dose of COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and partners BioNTech SE (NASDAQ:BNTX) and Pfizer...
...weeks after the first dose. The prior recommendation had been three weeks for Comirnaty from Pfizer...
...mRNA vaccines are not interchangeable with each other or with other COVID-19 vaccines. Separately, BioNTech and Pfizer...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

...unit of Johnson & Johnson (NYSE:JNJ), Moderna Inc. (NASDAQ:MRNA), Novavax Inc. (NASDAQ:NVAX) and Sanofi (Euronext:SAN; NASDAQ:SNY).A sixth company, Pfizer...
...statements by Pfizer Chairman and CEO Albert Bourla after its vaccine was authorized by FDA, Pfizer...
...risk was with Pfizer and all of the technical approach to the vaccine was with Pfizer...
BioCentury | Jan 22, 2021
Regulation

Jan. 21 Quick Takes: FDA approves ViiV’s long-acting HIV therapy; plus Menarini, Incyte, Moderna, Genentech

...majority owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Pfizer...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...molecules, versus biologics or gene therapies."SciNeuro’s management team includes CMO Qiuqing Ang, a veteran of GSK, Pfizer...
...Pharma Inc.; SVP & Head of Translational Science Danny Chen, formerly an executive director at Pfizer...
BioCentury | Jan 21, 2021
Product Development

How spike mutations in SARS-CoV-2 variants affect vaccines, therapies: Data Byte

...the two mRNA vaccines —from BioNTech SE (NASDAQ:BNTX) and Pfizer...
...N501Y substitution.The report comes two weeks after Pfizer...
...epitopes. Sandi Wong mRNA-1273 Comirnaty (PF-07302048, BNT162, BNT162b2) etesevimab (LY-CoV016, JS016) BioNTech SE Pfizer...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...in the towel. Prior failures in the class included Phase III disappointments for torcetrapib from Pfizer...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...after neoadjuvant treatment with J&J’s Erleada apalutamide, Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) and Pfizer...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...isolated from across the globe and assembled by pharmas including Merck & Co. Inc. (NYSE:MRK), Pfizer...
BioCentury | Jan 13, 2021
Product Development

mRNA vaccines still lead the COVID-19 pack: Data Byte

...of the vaccines that have had efficacy readouts since the mRNA vaccines from Moderna Inc. (NASDAQ:MRNA) and partners Pfizer...
...JNJ-78436735 from Johnson & Johnson (NYSE:JNJ), for which data are expected this month. Selina Koch Moderna Inc. Sinovac Biotech Ltd. Pfizer...
Items per page:
1 - 10 of 10101
BioCentury | Jan 23, 2021
Politics, Policy & Law

CMS rule should improve biosimilar Part D access, but isn’t silver bullet

...to biosimilars competing with the originator products. The prime example is the ongoing litigation between Pfizer...
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...CDC said the second dose of COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and partners BioNTech SE (NASDAQ:BNTX) and Pfizer...
...weeks after the first dose. The prior recommendation had been three weeks for Comirnaty from Pfizer...
...mRNA vaccines are not interchangeable with each other or with other COVID-19 vaccines. Separately, BioNTech and Pfizer...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

...unit of Johnson & Johnson (NYSE:JNJ), Moderna Inc. (NASDAQ:MRNA), Novavax Inc. (NASDAQ:NVAX) and Sanofi (Euronext:SAN; NASDAQ:SNY).A sixth company, Pfizer...
...statements by Pfizer Chairman and CEO Albert Bourla after its vaccine was authorized by FDA, Pfizer...
...risk was with Pfizer and all of the technical approach to the vaccine was with Pfizer...
BioCentury | Jan 22, 2021
Regulation

Jan. 21 Quick Takes: FDA approves ViiV’s long-acting HIV therapy; plus Menarini, Incyte, Moderna, Genentech

...majority owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Pfizer...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...molecules, versus biologics or gene therapies."SciNeuro’s management team includes CMO Qiuqing Ang, a veteran of GSK, Pfizer...
...Pharma Inc.; SVP & Head of Translational Science Danny Chen, formerly an executive director at Pfizer...
BioCentury | Jan 21, 2021
Product Development

How spike mutations in SARS-CoV-2 variants affect vaccines, therapies: Data Byte

...the two mRNA vaccines —from BioNTech SE (NASDAQ:BNTX) and Pfizer...
...N501Y substitution.The report comes two weeks after Pfizer...
...epitopes. Sandi Wong mRNA-1273 Comirnaty (PF-07302048, BNT162, BNT162b2) etesevimab (LY-CoV016, JS016) BioNTech SE Pfizer...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...in the towel. Prior failures in the class included Phase III disappointments for torcetrapib from Pfizer...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...after neoadjuvant treatment with J&J’s Erleada apalutamide, Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) and Pfizer...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...isolated from across the globe and assembled by pharmas including Merck & Co. Inc. (NYSE:MRK), Pfizer...
BioCentury | Jan 13, 2021
Product Development

mRNA vaccines still lead the COVID-19 pack: Data Byte

...of the vaccines that have had efficacy readouts since the mRNA vaccines from Moderna Inc. (NASDAQ:MRNA) and partners Pfizer...
...JNJ-78436735 from Johnson & Johnson (NYSE:JNJ), for which data are expected this month. Selina Koch Moderna Inc. Sinovac Biotech Ltd. Pfizer...
Items per page:
1 - 10 of 10101